TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Other Noncurrent Assets
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Other Noncurrent Assets of -$196.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$55.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$141.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $381.00K, a 807.14% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $373.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was $527.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was -$572.00K, a 179.67% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was $718.00K, a 233.95% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other noncurrent assets for fiscal 2022 was $215.00K, a 90.51% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$196.00K 10-Q · filed 2026-08-06 | $185.00K derived: sum of 3 quarters · filed 2026-08-06 | $558.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$141.00K 10-Q · filed 2026-05-06 | $240.00K derived: sum of 2 quarters · filed 2026-05-06 | $613.00K derived: sum of 3 quarters · filed 2026-05-06 | $511.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $754.00K derived: sum of 2 quarters · filed 2026-02-23 | $652.00K derived: sum of 3 quarters · filed 2026-08-06 | $527.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $373.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $271.00K derived: sum of 2 quarters · filed 2026-08-06 | $146.00K 10-Q · filed 2025-11-04 | $188.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$227.00K 10-Q · filed 2026-08-06 | -$185.00K derived: sum of 3 quarters · filed 2026-08-06 | -$210.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$125.00K 10-Q · filed 2026-05-06 | -$83.00K derived: sum of 2 quarters · filed 2026-05-06 | -$108.00K derived: sum of 3 quarters · filed 2026-05-06 | -$591.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $17.00K derived: sum of 2 quarters · filed 2026-02-23 | -$466.00K derived: sum of 3 quarters · filed 2026-02-23 | -$572.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$508.00K derived: sum of 2 quarters · filed 2025-11-04 | -$614.00K 10-Q · filed 2025-11-04 | -$504.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$483.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$589.00K 10-Q · filed 2025-08-06 | -$479.00K derived: sum of 3 quarters · filed 2026-02-23 | -$377.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$106.00K 10-Q · filed 2025-05-01 | $4.00K derived: sum of 2 quarters · filed 2026-02-23 | $106.00K derived: sum of 3 quarters · filed 2026-02-23 | $650.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $212.00K derived: sum of 2 quarters · filed 2026-02-23 | $756.00K derived: sum of 3 quarters · filed 2026-02-23 | $718.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $646.00K derived: sum of 2 quarters · filed 2024-11-13 | $608.00K 10-Q · filed 2024-11-13 | $748.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $506.00K 10-Q · filed 2024-08-08 | $646.00K derived: sum of 3 quarters · filed 2025-02-25 | $646.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$38.00K 10-Q · filed 2024-05-08 | $102.00K derived: sum of 2 quarters · filed 2025-02-25 | $102.00K derived: sum of 3 quarters · filed 2025-02-25 | $191.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $140.00K derived: sum of 2 quarters · filed 2025-02-25 | $229.00K derived: sum of 3 quarters · filed 2025-02-25 | $215.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $89.00K derived: sum of 2 quarters · filed 2023-11-09 | $75.00K 10-Q · filed 2023-11-09 | -$422.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $75.00K 10-Q · filed 2023-08-10 | -$422.00K derived: sum of 3 quarters · filed 2023-08-10 | $14.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$14.00K 10-Q · filed 2023-05-09 | -$511.00K derived: sum of 2 quarters · filed 2023-05-09 | -$75.00K derived: sum of 3 quarters · filed 2023-05-09 | $996.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$497.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$61.00K derived: sum of 2 quarters · filed 2023-03-17 | $1.01M derived: sum of 3 quarters · filed 2023-03-17 | $2.27M 10-K · filed 2023-03-17 |
| 2021-09-30 | $436.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.51M derived: sum of 2 quarters · filed 2022-11-09 | $2.76M 10-Q · filed 2022-11-09 | $2.81M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.33M 10-Q · filed 2022-08-11 | $2.37M derived: sum of 3 quarters · filed 2022-08-11 | $2.37M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.25M 10-Q · filed 2022-05-11 | $1.30M derived: sum of 2 quarters · filed 2022-05-11 | $1.30M derived: sum of 3 quarters · filed 2022-05-11 | $1.33M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $48.00K derived: sum of 2 quarters · filed 2022-03-14 | $75.00K derived: sum of 3 quarters · filed 2022-03-14 | $75.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $27.00K derived: sum of 2 quarters · filed 2021-11-10 | $27.00K 10-Q · filed 2021-11-10 | $27.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $27.00K 10-Q · filed 2021-08-05 | $27.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $6.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $6.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |